Public Release: 

Mayo researchers explore reasons for complications with kidney failure patients

Mayo Clinic

ROCHESTER, Minn. -- Mayo Clinic researchers searching for explanations of high mortality rates among kidney failure patients undergoing hemodialysis are focusing their attention on the use of heparin, a drug used to reduce clotting of the blood.

Their study in the August issue of Mayo Clinic Proceedings is a preliminary look at one aspect affecting the health of patients who undergo hemodialysis. In the study, they found patients who had a higher level of adverse outcomes also had elevated levels of heparin antibodies in their blood. The authors believe this is the first study examining this association.

However, Robert McBane, M.D., a Mayo Clinic cardiovascular disease specialist who led the study, cautions that these results are preliminary.

"These results are thought-provoking and hypothesis-generating, but at this point we need more study," says Dr. McBane. "Patients requiring hemodialysis have a high mortality rate for reasons which are not clear. The search for variables contributing to this mortality rate is of prime importance."

Heparin is an anticoagulant, which is usually used to prevent the formation of blood clots in the blood vessels that can prove harmful.

For patients with end-stage renal disease (kidney failure), hemodialysis is the most common form of therapy. Recent figures show more than 85 percent of the approximately 379,000 patients with the disease were treated this way. In hemodialysis, the patient's blood is passed through a machine to clean it, similar to what the kidneys might do if the body was functioning normally. Heparin must be used to prevent clotting of the blood in the dialysis machine in order to safely perform hemodialysis. At this time, there are no other widely-used alternatives to heparin. The results of this analysis, if confirmed by others, might stimulate the search for better anticoagulants that can be used in hemodialysis.

The study found that the presence of heparin antibodies in hemodialysis patients was associated with more adverse outcomes compared with hemodialysis patients without detectable antibodies. If the findings are confirmed by others, physicians might test for the presence of these antibodies to determine if a patient might be at an above-average risk for complications.

Co-authors in the study include Lourdes Pena de la Vega, M.D., Randal Miller, Margaret Benda, Diane Grill, Matthew Johnson, and James McCarthy, M.D.

In an editorial in the same issue of Mayo Clinic Proceedings, Donald Arnold, M.D., and John Kelton, M.D., of the Department of Medicine, Michael G. DeGroote School of Medicine at McMaster University in Hamilton, Ontario, Canada, say the study adds to the evidence that the heparin antibodies may be an indicator of problems even if other symptoms aren't evident. But they also say further study is needed.

###

A peer-review journal, Mayo Clinic Proceedings publishes original articles and reviews dealing with clinical and laboratory medicine, clinical research, basic science research and clinical epidemiology. Mayo Clinic Proceedings is published monthly by Mayo Foundation for Medical Education and Research as part of its commitment to the medical education of physicians. The journal has been published for more than 75 years and has a circulation of 130,000 nationally and internationally. Copies of the articles are available online at www.mayoclinicproceedings.com.

To obtain the latest news releases from Mayo Clinic, go to www.mayoclinic.org/news. MayoClinic.com (www.mayoclinic.com) is available as a resource for your health stories.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.